- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-HER-2-positive gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 383KB)
Nivolumab – March 2022
Nivolumab (HER-2-neg gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
1 July 2022